- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Clinical-grade bispecific, aliquoted from commercial EU-Licensed medicines
Showing all 6 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
EGFR , MET |
Bispecific Antibody |
Rybrevant® |
50 mg/ml |
– |
7 mg |
-80°C |
11/2023 |
365,00 € |
||
CD19 , CD3 |
Bispecific Antibody |
Blincyto® |
0,0125 mg/mL |
– |
0,002 mg |
2-8°C/-80°C |
12/2024 |
739,00 € |
||
Clotting Factor IXa and X |
Bispecific Antibody |
Hemlibra® |
30 mg/mL |
– |
2 mg |
-80°C |
09/2023 |
727,00 € |
||
VEGF-A |
Monoclonal Antibody |
Vabysmo® |
120 mg/mL |
– |
2.4 mg |
tba |
tba |
618,00 € |
||
CD20 , CD3 |
Bispecific Antibody |
Lunsumio® |
1 mg/mL |
– |
0.05 mg |
tba |
tba |
316,00 € |
||
CD3 , TCR targeting domain |
Bispecific fusion protein |
Kimmtrak® |
0,2 mg/mL |
– |
0.01 mg |
tba |
tba |
4.602,00 € |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin